A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
This study is a randomized, double-blind, placebo-controlled Phase II study in participants with moderate-to-severe Sjögren's disease. Eligible participants will be randomized to receive IBI355 or placebo during the double-blind treatment period.
The study will evaluate the efficacy of IBI355 in reducing systemic disease activity and improving patient-reported symptoms and disease-related functional outcomes. Safety and tolerability will be assessed throughout the study. Pharmacokinetic, immunogenicity, pharmacodynamic, and other relevant clinical assessments will also be performed as specified in the protocol.
The results of this study are intended to characterize the efficacy and safety profile of IBI355 in participants with Sjögren's disease and to support its further clinical development.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: xiaoyan li
- Numéro de téléphone: 18756032014
- E-mail: xiaoyan.li@innoventbio.com
Lieux d'étude
-
-
Anhui
-
Hefei, Anhui, Chine, 230001
- The First Affiliated Hospital of University of Science and Technology of China
-
Chercheur principal:
- Xiaomei Li, M.D.
-
Contact:
- Xiaomei Li
- Numéro de téléphone: 13866795533
- E-mail: lixiaomei@fsmy@aliyun.com
-
Sous-enquêteur:
- Zhen Tan, M.D.
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥18 and ≤75 years.
- Diagnosis of Sjögren's syndrome per 2016 ACR/EULAR classification criteria.
- Duration of Sjögren's syndrome diagnosis ≤7.5 years.
- Serum anti-Ro/SSA (Ro60 and/or Ro52) positive.
- Stimulated whole saliva flow rate ≥0.05 mL/min at screening.
- Baseline ESSDAI score ≥5 in ≥1 of the following domains: systemic, lymphadenopathy, glandular, articular, cutaneous, renal, hematologic, biological.
- Stable background therapy (hydroxychloroquine ≤400 mg/day, methotrexate ≤25 mg/week, or azathioprine ≤150 mg/day) for ≥12 weeks with stable dose ≥8 weeks prior to randomization.
- Stable oral corticosteroid dose (≤10 mg/day prednisone equivalent) for ≥4 weeks prior to randomization.
Exclusion Criteria:
- Known hypersensitivity to IBI355 or its excipients.
- Pregnancy or breastfeeding.
- Uncontrolled interstitial lung disease (ILD) associated with Sjögren's syndrome (e.g., FVC <70% predicted, ClinESSDAI pulmonary domain indicating severe activity, or NYHA Class III/IV dyspnea).
- Active or untreated latent tuberculosis (IGRA-positive without ≥1 month prophylactic treatment).
- Chronic hepatitis B (HBsAg+), hepatitis C (HCV RNA+), HIV, or syphilis.
- Prior use of rituximab, other anti-CD20 agents, or other biologics targeting CD40/CD40L, BAFF/APRIL, or CTLA-4 within 6 months prior to randomization.
- Use of JAK/TYK inhibitors within 8 weeks prior to randomization.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Part A: IBI355 group
IBI355,IV,corresponding dose regimen according to study cohort( Part A) . |
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design IBI355,IV,corresponding dose regimen according to study design |
|
Expérimental: Part B: Telitacicept 160 mg group
Participants received telitacicept 160 mg SC QW from Week 0 to Week 24. Follow-up through Week 36 |
Telitacicept 160 mg SC QW × 24 doses (Weeks 0-24). |
|
Expérimental: Part A: Placebo group(IBI355-matched)
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design |
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design IBI355,IV,corresponding dose regimen according to study design |
|
Expérimental: Part B: Placebo group (Telitacicept-matched)
Participants received matching placebo SC QW from Week 0 to Week 24. Follow-up through Week 36. |
Matching placebo of Talitacicept ,SC QW × 24 doses. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
Délai: Baseline and Week 24
|
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement. |
Baseline and Week 24
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in ESSDAI Score at Weeks 12 and 48
Délai: Baseline to Weeks 12 and 48
|
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement. |
Baseline to Weeks 12 and 48
|
|
Change from Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Weeks 12, 24, and 48
Délai: Baseline to Weeks 12, 24, and 48
|
The EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is a patient-reported measure assessing dryness, fatigue, and pain. Each domain is rated on a 0-to-10 numerical rating scale, and the total ESSPRI score is calculated as the mean of the three domain scores, ranging from 0 to 10. Higher scores indicate greater symptom severity. A decrease from baseline indicates improvement. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in Stimulated Salivary Flow (sSF) Rate at Weeks 12, 24, and 48
Délai: Baseline to Weeks 12, 24, and 48
|
Stimulated salivary flow rate will be measured according to the protocol-specified procedure. An increase from baseline indicates an improvement in stimulated salivary gland function. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in Schirmer Test at Week 48
Délai: Baseline to Week 48
|
The Schirmer test is used to assess tear production and is reported as the length of wetting of the test strip over 5 minutes, measured in millimeters (mm/5 min). Higher values indicate greater tear production. |
Baseline to Week 48
|
|
Change from Baseline in Sj?gren's Tool for Assessing Response (STAR) Score at Week 48
Délai: Baseline to Week 48
|
The Sj?gren's Tool for Assessing Response (STAR) is a composite assessment of treatment response in Sj?gren's disease incorporating systemic disease activity, patient-reported symptoms, and biological and glandular domains. Higher scores indicate a greater treatment response. |
Baseline to Week 48
|
|
Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Weeks 12, 24, and 48
Délai: Baseline to Weeks 12, 24, and 48
|
The FACIT-Fatigue scale is a 13-item patient-reported measure of fatigue. The total score ranges from 0 to 52, with higher scores indicating less fatigue and better functioning. An increase from baseline indicates improvement. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index Score at Weeks 12, 24, and 48
Délai: Baseline to Weeks 12, 24, and 48
|
The EQ-5D-5L is a standardized measure of health status assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels of severity. Responses are converted to an EQ-5D-5L index score using the prespecified value set, with higher index scores indicating better health status. |
Baseline to Weeks 12, 24, and 48
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Délai: From the first dose of study intervention through Week 48
|
The number and percentage of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) will be assessed throughout the study. |
From the first dose of study intervention through Week 48
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies musculo-squelettiques
- Maladies de la bouche
- Maladies stomatognathiques
- Arthrite
- Maladies articulaires
- Maladies rhumatismales
- Maladies du tissu conjonctif
- Maladies auto-immunes
- Maladies du système immunitaire
- Maladies oculaires
- Arthrite, rhumatoïde
- Xérostomie
- Maladies des glandes salivaires
- Syndromes de sécheresse oculaire
- Maladies de l'appareil lacrymal
- Maladies de la peau et du tissu conjonctif
- Le syndrome de Sjogren
- télitacicept
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- CIBI355A201
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .